JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies

Abstract

JAK/STAT signaling pathway is one of the important regulatory signaling cascades for the myriad of cellular processes initiated by various types of ligands such as growth factors, hormones, and cytokines. The physiological processes regulated by JAK/STAT signaling are immune regulation, cell proliferation, cell survival, apoptosis and hematopoiesis of myeloid and non-myeloid cells. Dysregulation of JAK/STAT signaling is reported in various immunological disorders, hematological and other solid malignancies through various oncogenic activation mutations in receptors, downstream mediators, and associated transcriptional factors such as STATs. STATs typically have a dual role when explored in the context of cancer. While several members of the STAT family are involved in malignancies, however, a few members which include STAT3 and STAT5 are linked to tumor initiation and progression. Other STAT members such as STAT1 and STAT2 are pivotal for antitumor defense and maintenance of an effective and long-term immune response through evolutionarily conserved programs. The effects of JAK/STAT signaling and the persistent activation of STATs in tumor cell survival; proliferation and invasion have made the JAK/STAT pathway an ideal target for drug development and cancer therapy. Therefore, understanding the intricate JAK/STAT signaling in the pathogenesis of solid malignancies needs extensive research. A better understanding of the functionally redundant roles of JAKs and STATs may provide a rationale for improving existing cancer therapies which have deleterious effects on normal cells and to identifying novel targets for therapeutic intervention in solid malignancies.

In Peripheral Blood Mononuclear Cells Helicobacter pylori Induces the Secretion of Soluble and Exosomal Cytokines Related to Carcinogenesis

“…In the PPI network, we found that IL-1β, IL-6, TNF-α, IL-10, IL-17A, IL-21, and IL-22 interact directly and indirectly with proteins that participate in the NF-κB, MAPK, PI3K-Akt, mTOR, FoxO, and Jak-STAT signaling pathways. The largest number of these pathways contribute to the regulation of proliferation, differentiation, growth, apoptosis, angiogenesis, cell survival, adhesion, migration, invasion, epithelial-mesenchymal transition, resistance to oxidative stress, metabolism, autophagy, inflammation, and metastasis processes that contribute to carcinogenesis or tumor progression [ 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 ]. Additionally, we found that TNF-α interacts with proteins that are involved in the NF-κB, MAPK, mTOR, and apoptosis signaling pathways.…”

Construction of immunotherapy-related prognostic gene signature and small molecule drug prediction for cutaneous melanoma

“…This suggests that PRF1 mediates tumor-infiltrating T lymphocytes (TIL) oligoclonal amplification-enhanced Th1 (helper T cell type I)-skewed cellular immunity during nivolumab treatment ( 53 ). STAT1 (signal transducers and activators of transcription 1) is a family of cytosolic proteins that, upon activation, can translocate to the nucleus and bind DNA, which has dual signal transduction and transcriptional control functions ( 54 , 55 ). Hypermethylation in the promoter region of the SOCS3 gene was discovered to reduce SOCS3 protein expression in some CM patients.…”

Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies

“…Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that belongs to the JAK-STAT signaling pathway, and becomes activated in response to cytokines, growth factors, MAPK, and c-src non-receptor tyrosine kinases [ 109 ]. Overexpression or increased activation of STAT3 is implicated in several hematologic malignancies, including acute leukemias, chronic lymphocytic leukemia, chronic myelogenous leukemia, large granular leukemia, as well as Hodgkin’s and non-Hodgkin’s lymphomas, and multiple myeloma [ 110 ].…”